FSR is pleased to announce the appointment of Michael Klingher to the FSR Board of Directors. Klingher has over 35 years’ experience as an investment banker and investor in commercial real estate, working with Goldman Sachs and in managing his own real estate opportunity fund focused on the hospitality sector. Klingher obtained his MBA degree from Harvard Business School and a JD degree from Harvard Law School. He is Trustee Emeritus of Wesleyan University and also served for over 10 years on the board of the Westport Country Playhouse, a regional theater in Westport, CT, including 3 years as Board Chair.
“We are thrilled to welcome Michael Klingher to the FSR Board of Directors,” said Dr. Louise Perkins, FSR Board President. “Mr. Klingher brings a wealth of experience and business expertise to the board. We know Mr. Klingher’s unique perspectives, leadership, and passion will enhance FSR’s Board of Directors in our pursuit of a cure and in improving the lives of those impacted by sarcoidosis.”
“I feel strongly about FSR’s mission and their efforts to have a positive impact on the lives of people with sarcoidosis. I hope my experience will enhance FSR’s efforts to advance research and provide patient support,” said Klingher. “Additionally, I am also committed to helping FSR lead the way to a more timely and accurate diagnosis of this rare disease, improved care and treatment, and to reduce the barriers associated with underserved individuals impacted by sarcoidosis.”
FSR’s Board of Directors is comprised of leaders from the business, medical, and patient communities. The Board is responsible for the strategic direction of the foundation. Together with the organization’s Scientific Advisory Board (SAB), comprised of international sarcoidosis experts, they help advance FSR’s mission by providing strategic advice on its scientific and research programs.